High residual platelet aggregation in patients with coronary artery disease: a new methodological approach to detection

 Aim. To develop a new methodological approach to assessment of collagen-induced platelet aggregation in patients with coronary artery disease (CAD) and to determine the quality of various methods for detecting high residual platelet reactivity (HRPR) to predict the risk of myocardial perfusion disturbance.

Materials and methods. 36 patients (10 men and 26 women) aged 41–83 years and having stable CAD were examined. All patients had been undergoing continuous antiaggregation therapy for 6 months. We evaluated platelet aggregation using a laser analyzer with collagen as an aggregation inducer by the standard method 1 and our own patented method 2. The degree of platelet aggregation (%) and the size of aggregates in relative units (r.u.) in platelet-rich plasma were estimated. Myocardial perfusion scintigraphy with 99mTc-methoxy-isobutylisonitrile was performed according to a two-day stress-rest protocol. The summed stress score (SSS) values were used for analysis. SSS < 4 was regarded as normal myocardial perfusion.

Results. The degree of platelet aggregation according to method 1 was 12 (5; 64)%, the aggregate size was 3 (2; 7) r.u. The degree of platelet aggregation according to method 2 was 44 (13; 78)%, and the aggregate size was 5 (4; 8) r.u. Method 2 allowed to diagnose the presence of myocardial ischemia with an aggregation degree ≥ 44.9% with sensitivity of 84% and specificity of 92% (area under the curve (AUC) = 0.89; p < 0.0001; odds ratio (OR) 2.18; 95% confidence interval (CI) 0.57–0.98) and an increase in aggregate size ≥ 4.80 r.u. with sensitivity of 84% and specificity of 84% (AUC = 0.95; p < 0.00001; OR 5.83; 95% CI 0.72–0.99).

Conclusion. In patients with CAD, detection of high rates of collagen- induced platelet aggregation using the patented technique is associated with the risk of impaired myocardial perfusion. The developed new  methodological approach to detection of HRPR allowed to determine high risk of atherothrombotic complications in additional 22% of the examined patients. 

1. Мирзаев К.Б., Андреев Д.А., Сычев Д.А. Оценка агрегации тромбоцитов в клинической практике. Рациональная фармакотерапия в кардиологии. 2015; 11 (1): 85–91. DOI: 10.20996/1819-6446-2015-11-1-85-91.

2. Stone G.W., Witzenbichler B., Weisz G., Rinaldi M.J., Neumann F.-J., Metzger D.C. et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013; 382 (9892): 614–623. DOI: 10.1016/S0140-6736(13)61170-8.

3. Трубачева О.А., Суслова Т.Е., Кологривова И.В., Гусакова А.М., Павлюкова Е.Н., Шнайдер О.Л., Петрова И.В. Способ определения резистентности тромбоцитов к антиагрегатным препаратам у пациентов с ишемической болезнью сердца. Патент России RU 2686700 C1. Опубл. 30.04.2019.

4. Завадовский К.В., Гуля М.О., Саушкин В.В., Саушкина Ю.В., Лишманов Ю.Б. Совмещенная однофотонная эмиссионная и рентгеновская компьютерная томография сердца: методические аспекты. Вестник рентгенологии и радиологии. 2016; 97 (4): 235–242. DOI: 10.20862/0042-4676-2016-97-4-8-15.

5. Udell J.A., Bonaca M.P., Collet J.-P., Lincoff A.M., Kereiakes D.J., Costa F. et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal. 2016; 37 (4): 390–399. DOI: 10.1093/eurheartj/ehv443.

6. Aradi D., Storey R.F., Komocsi A., Trenk D., Gulba D., Kiss R.G. et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal. 2014; 35 (4): 209–215. DOI: 10.1093/eurheartj/eht375.

7. Jastrzebska M., Marcinowska Z., Oledzki S. et al. Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease. Journal of Physiology and Pharmacology. 2018; 69 (4): 595–605. DOI: 10.26402/jpp.2018.4.10.

8. Бакунович А.В., Буланова К.Я., Лобанок Л.М. Молекулярные механизмы агрегации тромбоцитов. Журнал Белорусского государственного университетата. Экология. 2017; 4: 40–51.